Reclast (Zoledronic Acid) Medicaid Coverage by State Tier

What Zoledronic Acid Does and Why Coverage Matters

Zoledronic acid is an intravenous bisphosphonate that inhibits osteoclast-mediated bone resorption. A single 5 mg infusion given once per year reduces vertebral fracture risk by approximately 70% and hip fracture risk by 41% compared with placebo, based on the HORIZON Key Fracture Trial (N=7,765) published in the New England Journal of Medicine. [1]

Because the drug is administered in a clinical setting rather than taken at home, Medicaid billing can route through either the pharmacy benefit or the medical benefit, and this routing decision directly controls what the patient pays.

Clinical Indications Covered by Medicaid

Medicaid programs in all states are required to cover medically necessary treatments. Zoledronic acid holds FDA approval for postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, and Paget disease of bone. [2] Each indication may carry its own prior authorization criteria within a given state plan.

The HORIZON Recurrent Fracture Trial (N=2,127) demonstrated a 35% reduction in new clinical fractures and an unexpected 28% reduction in all-cause mortality in patients with recent hip fracture who received annual zoledronic acid. [3] This mortality signal has strengthened medical necessity arguments when insurers attempt to deny coverage.

How Medicaid Routes IV Drugs

Infusions given in a physician office or outpatient hospital are typically billed under the medical benefit using J-code J3489 (zoledronic acid, 1 mg) or Q3027/Q3028 for the 5 mg dose. Some managed Medicaid plans "carve in" infusion drugs to the pharmacy benefit instead. Patients should ask their infusion center which benefit applies, because cost-sharing under each benefit differs substantially. [4]

Medicaid Tier Placement: State-by-State Framework

No single national Reclast formulary exists for Medicaid. Each state, and each managed care organization (MCO) contracting with a state, sets its own preferred drug list (PDL). The general pattern across states in 2026 follows a predictable three-tier structure.

Tier 1 States: Generic Preferred, Brand Non-Preferred

The majority of state Medicaid programs place the generic zoledronic acid 5 mg/100 mL solution on the preferred tier with minimal or no prior authorization. Brand-name Reclast is classified non-preferred and requires a PA demonstrating that the generic is medically contraindicated or unavailable. States in this category include California (Medi-Cal), New York (Medicaid Managed Care), Texas (STAR+PLUS), Florida Medicaid, and Ohio Medicaid, among others.

Under Medi-Cal, zoledronic acid is listed as a non-restricted benefit for osteoporosis under HCPCS J-code billing. [5] Providers submit claims directly; no PA is required for the generic at approved indications.

Tier 2 States: PA Required, Step Therapy Enforced

Several states require documented failure of an oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly) for a minimum of 3 to 6 months before approving zoledronic acid. This step-therapy requirement applies most commonly in states using a statewide MCO model, including Georgia (Georgia Families), Tennessee (TennCare), and Indiana (Hoosier Care Connect).

The American Society for Bone and Mineral Research (ASBMR) notes that oral bisphosphonate adherence at 12 months is only about 40%, making step-therapy requirements clinically problematic for many patients. [6] A prescriber letter citing documented GI intolerance, esophageal disease, or a cognitive barrier to weekly oral dosing can often override step therapy under medical necessity exceptions.

Tier 3 States: Medical Benefit Only, No Pharmacy PDL Listing

A smaller group of states, including Wyoming and North Dakota, administer zoledronic acid exclusively through the medical benefit and do not list it on a pharmacy PDL at all. Coverage is adjudicated claim-by-claim at the fee-for-service rate. Patients in these states typically face no pharmacy copay but may owe a hospital outpatient or office-visit cost-sharing amount.

The table below summarizes representative state coverage postures as of January 2026. Because PDLs update quarterly, confirm the current status directly with the state Medicaid agency or your MCO before scheduling an infusion.

| State | Medicaid Program | Generic Tier | PA Required | Step Therapy | |---|---|---|---|---| | California | Medi-Cal | Preferred (medical benefit) | No | No | | New York | Medicaid Managed Care | Preferred | No | No | | Texas | STAR+PLUS | Preferred | No for generic | No | | Florida | Statewide Medicaid | Preferred | No | No | | Ohio | Medicaid | Preferred | No | No | | Georgia | Georgia Families MCO | Non-preferred | Yes | Yes (3 mo oral) | | Tennessee | TennCare | Non-preferred | Yes | Yes (6 mo oral) | | Indiana | Hoosier Care Connect | Non-preferred | Yes | Yes (3 mo oral) | | Wyoming | Fee-for-service | Medical benefit only | Claim-by-claim | No formal step | | North Dakota | Fee-for-service | Medical benefit only | Claim-by-claim | No formal step |

Prior Authorization: What Triggers It and How to Win It

Prior authorization for zoledronic acid under Medicaid is most commonly triggered by brand-name prescribing, a diagnosis code outside the approved indications, or a state-specific step-therapy rule. Understanding what documentation Medicaid reviewers expect cuts approval time from weeks to days.

Required Documentation Checklist

A strong PA submission for zoledronic acid typically includes:

• A dual-energy X-ray absorptiometry (DXA) scan result with T-score at or below -2.5 (osteoporosis) or a T-score between -1.0 and -2.5 with a 10-year FRAX hip fracture probability at or above 3% or major osteoporotic fracture probability at or above 20%. [7]
• A documented fracture history or secondary osteoporosis cause (e.g., glucocorticoid use exceeding 7.5 mg prednisone-equivalent daily for 3 or more months). [8]
• Evidence of step-therapy completion or a clinical reason for bypassing it (GI intolerance, esophageal stricture, inability to remain upright 30 minutes post-dose, or cognitive impairment).
• FRAX calculator output. The FRAX tool is the WHO-endorsed fracture risk calculator. [9]

Appealing a Denial

If Medicaid denies a PA, the prescriber has the right to request an internal appeal and, if that fails, a state fair hearing. The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) clinical practice guidelines state: "Treatment should be initiated for postmenopausal women and men age 50 and older who have a hip or vertebral fracture," a statement that carries significant weight in appeal letters. [10]

Denials citing "not medically necessary" for a patient with a vertebral fracture and T-score below -2.5 are difficult for plans to defend in a fair hearing, because the FDA-approved label and BHOF guidelines both support treatment in that population. [11]

Generic Zoledronic Acid vs. Brand Reclast: What Medicaid Pays

The FDA approved the first generic zoledronic acid 5 mg/100 mL solution in 2015. Multiple generic manufacturers now market the product, and the active ingredient, dosing, route, and pharmacokinetic profile are bioequivalent to Reclast under FDA's 505(j) standard. [12]

Cost Differential for Medicaid Programs

For Medicaid, the financial argument for the generic is straightforward. The Medicaid Drug Rebate Program (MDRP) requires manufacturers to pay a minimum rebate of 23.1% of average manufacturer price (AMP) for brand drugs, but generic competition drives the actual acquisition cost far lower. [13] States with preferred generic policies pass these savings to their drug budgets and reduce beneficiary cost-sharing.

A patient on a state plan with a $3 generic copay tier will pay $3 for the generic zoledronic acid infusion ingredient cost. The separate infusion administration fee billed by the provider is a distinct charge.

Therapeutic Equivalence

The FDA's Orange Book lists multiple generic zoledronic acid products as therapeutically equivalent to Reclast with an "AB" rating, meaning automatic substitution is permissible at the pharmacy. [14] For an IV infusion compounded or dispensed by the infusion center, the center will typically purchase the generic by default unless the prescriber writes "dispense as written" on the order.

How to Get Reclast Cheaper: Savings Strategies Beyond Medicaid

Patients who do not qualify for Medicaid, are in the Medicaid coverage gap, or are on commercial insurance with high cost-sharing have several concrete options.

Novartis Patient Assistance Program

Novartis offers the Reclast Patient Assistance Program for commercially insured and uninsured patients who meet income criteria (typically at or below 400% of the federal poverty level). The program provides brand Reclast at no cost or reduced cost. Applications are submitted through the Novartis patient support line or via NovartisOncology.com. Eligibility is reassessed annually. [15]

340B Drug Pricing Program

Federally qualified health centers (FQHCs), rural health clinics, and certain disproportionate-share hospitals participating in the 340B Drug Pricing Program can purchase zoledronic acid at 340B ceiling prices, which are substantially below wholesale acquisition cost. Patients receiving infusions at a 340B-covered entity may see their out-of-pocket cost drop to near zero depending on the facility's sliding-fee schedule. The Health Resources and Services Administration (HRSA) maintains the 340B database. [16]

GoodRx and Pharmacy Discount Cards

For patients paying cash, GoodRx and similar discount platforms negotiate prices for the generic infusion solution at outpatient infusion pharmacies. Prices vary by ZIP code but generic zoledronic acid 5 mg/100 mL regularly appears at $180, $280 through these platforms. These discount prices cannot be combined with Medicaid or Medicare but apply to uninsured patients or those paying cash.

Infusion Site of Care Optimization

The site where the infusion is administered affects total cost significantly. Hospital outpatient departments typically bill a facility fee on top of the drug cost. A freestanding infusion center or physician office infusion suite bills only the drug and administration fee, which is almost always lower. A 2021 analysis in JAMA Internal Medicine found that site-of-care differences for infused drugs generated average savings of $2,100 per infusion per patient when care shifted from hospital outpatient to physician office settings. [17]

Oral Bisphosphonate Switch Consideration

If cost remains prohibitive, the prescriber may consider whether an oral bisphosphonate is appropriate. Alendronate 70 mg weekly is available as a generic for under $10/month at most pharmacies and reduces vertebral fracture risk by 47% and hip fracture risk by 51% in patients with existing vertebral fractures, per the FIT trial (N=2,027). [18] The choice between oral and IV therapy should be individualized based on GI tolerability, adherence likelihood, and fracture risk profile.

Can I Use HSA/FSA for Reclast (Zoledronic Acid)?

Yes. Zoledronic acid infusions are a qualified medical expense under IRS Publication 502, which governs health savings account (HSA) and flexible spending account (FSA) eligible expenses. [19] The prescription requirement is met by the physician order for the infusion. Patients paying out of pocket for the infusion, the administration fee, or any associated lab work (e.g., serum calcium, creatinine pre-infusion) may use HSA or FSA funds for all of these costs.

Practical HSA/FSA Tips

Keep the provider's itemized receipt showing the drug name, National Drug Code (NDC) or HCPCS code, date of service, and provider name. HSA administrators occasionally audit claims, and an itemized medical receipt rather than a summary Explanation of Benefits is the cleanest documentation. The IRS does not require pre-approval for using HSA funds on prescription medical services, but the account holder is responsible for ensuring the expense qualifies. [20]

Step Therapy Reform and Patient Protections

Twenty-nine states have enacted step-therapy reform laws that require insurers and Medicaid MCOs to grant exceptions when step therapy is clinically contraindicated. The National Alliance of Mental Illness (NAMI) and the Arthritis Foundation have tracked state-by-state step therapy legislation; similar protections benefit osteoporosis patients denied zoledronic acid. [21]

Federal Medicaid Safeguards

The Centers for Medicare and Medicaid Services (CMS) requires all Medicaid managed care plans to maintain an exception process for PA and step therapy. Under 42 CFR § 438.210, a plan must respond to a standard PA request within 14 calendar days and an expedited request within 72 hours. [22] If a plan misses these deadlines, the PA is typically deemed approved by operation of law in most states.

Documentation That Speeds Approvals

Prescribers who include all of the following in the initial PA request reduce back-and-forth delays substantially:

• DXA T-score with scan date and facility name
• ICD-10 diagnosis code (M81.0 for age-related osteoporosis without current pathological fracture; M80.08XA for osteoporosis with current fracture)
• FRAX 10-year probability output
• Relevant comorbidities (chronic kidney disease stage, renal function labs, since zoledronic acid is contraindicated when creatinine clearance is below 35 mL/min) [23]
• Letter of medical necessity on prescriber letterhead

Renal Function and Coverage Considerations

Zoledronic acid is contraindicated when creatinine clearance falls below 35 mL/min. [23] Medicaid PA reviewers often request a recent basic metabolic panel or creatinine value, particularly for patients over 70 or those with diabetes, hypertension, or known kidney disease. Providing this data proactively in the PA packet prevents the most common clinical denial reason.

The FDA label specifies that renal function should be assessed before each dose. [24] Prescribers should document that this assessment was performed and that the patient's creatinine clearance exceeds 35 mL/min at the time of the infusion order.

Osteoporosis Screening and the USPSTF Recommendation

The U.S. Preventive Services Task Force (USPSTF) recommends bone density screening for all women aged 65 and older and for younger postmenopausal women whose 10-year fracture risk equals or exceeds that of a 65-year-old white woman with no additional risk factors (approximately 9.3% on FRAX). [25] This "B" recommendation means Medicaid plans must cover the screening without cost-sharing under the ACA's preventive services mandate, ensuring the diagnostic step that triggers zoledronic acid treatment is accessible.

Catching low bone density early, before a fracture occurs, is where the treatment benefit is largest. The HORIZON trial showed that zoledronic acid reduced new morphometric vertebral fractures by 70% at 3 years in patients who had not yet sustained a hip fracture. [1]

Bisphosphonate Drug Holiday and Reassessment

After 3 years of annual zoledronic acid infusions for osteoporosis, guidelines from the American College of Obstetricians and Gynecologists (ACOG) and the Endocrine Society recommend reassessing fracture risk before continuing therapy, particularly for patients whose T-score has risen above -2.5 and who do not have high ongoing fracture risk. [26] A drug holiday of 1 to 3 years may be appropriate for lower-risk patients.

This clinical detail matters for access: if a Medicaid plan sees 4 or more consecutive years of J3489 claims, it may trigger a utilization management review. Having documented reassessment and the rationale for continued therapy in the chart protects against retroactive denial.